South Korea-based healthcare company Yuyu Pharma announced on Tuesday that it has completed a strategic investment in Dalan Animal Health, a US-based biotechnology company advancing an innate immunity-based platform for developing vaccines for honeybees and shrimp.
This investment will enable the company to continue to expand its platform across new species, exploring novel applications for poultry as well as other aquaculture species.
Robert Wonsang Yu, CEO of Yuyu Pharma, said: "Yuyu Pharma is moving decisively into new areas of animal health where scientific innovation can create lasting global impact. Bees, shrimp, and other essential species play foundational roles in food systems and environmental stability. Our investment in Dalan reflects a clear ambition: to engage directly with technologies that will shape the next generation of global animal health solutions."
Anixa Biosciences' breast cancer vaccine technology granted first Korean patent
Transgene expands myvac platform into non-small cell lung cancer with TG4070
Replicate Bioscience awarded Gates Foundation grant to advance srRNA vaccine candidates for TB
Bavarian Nordic secures DKK700m government vaccine contract
Anixa secures Canadian patent milestone for ovarian cancer vaccine
Transgene to present preclinical TG-MVA mpox vaccine data at World Congress on Infectious Diseases
4basebio secures clinical supply agreement for Phase II immunotherapy trial
GSK's Arexvy gains expanded approval in Japan for at-risk adults aged 18-49
Bavarian Nordic secures USD97m US vaccine contract expansion and raises 2026 outlook
Anixa Biosciences reports extended survival signals in Phase 1 ovarian cancer CAR-T trial
4basebio introduces enzymatic ssDNA platform for gene editing applications
hVIVO secures Phase III human challenge trial contract with ILiAD Biotechnologies
Sanofi's Nuvaxovid demonstrates superior tolerability to Moderna's mNEXSPIKE in phase 4 study
hVIVO signs influenza human challenge trial agreement with Traws Pharma